Skip to main content

Table 3 Summary of treatment regimen, local control, progression free survival, overall survival and late toxicity in recent study compared to the present study

From: SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience

Author, study (ref.)

Patients (n)

SBRT dose (Gy/fraction)

CT gemcitabina-based

FFLP (%)

PFS (months)

OS (months)

GI toxicity ( ≥ G2) (%)

Koong[12]

15

15–25 Gy/1fx

no

77%

2

11 from diagnosis

none

Hoyer[13]

22

45 Gy/3fx

no

57%

4.8

5.7 from diagnosis

18%

Schellenberg[14]

16

25 Gy/1fx

sequential chemotherapy

81%

9

11.4 from diagnosis

47%

Chang[15]

77

25 Gy/ 1fx

For same patients prior CT

84%

-

11.4 from diagnosis

13%

Schellenberg[16]

20

25 Gy/1fx

sequential chemotherapy

94%

9.2

11.8 from diagnosis

20%

Polistina[17]

33

30 Gy/3fx

Prior chemotherapy

82.6%

7.3

10.6

none

Didolkar[18]

85

15–30 Gy/3 fx

sequential chemotherapy

91.7%

-

18.6 from diagnosis 8.6 from SBRT

22%

Mahadevan[19]

39

24-36 Gy/3fx

sequential chemotherapy

85%

15 from diagnosis

20 from diagnosis

9%

Rwigema[20]

71

18–25 Gy/1fx

no

64.8%

-

10.3

10%

Present study

30

36-45Gy/6 fx

Prior chemotherapy

85% (96% for group of 45 Gy)

8 from SBRT 14 from diagnosis

11 from SBRT 19.5 from diagnosis

none

  1. Dx%: dose received by at least x% of the volume; Vx%: volume receiving at least x% of the dose.